Register for our free email digests:
Division of Johnson & Johnson
Latest From Parke-Davis
This latest roundup includes EFPIA's appointment of Nathalie Moll to director general, CEO appointments by YposKesi and Symbiomix Therapeutics, as well as various executive appointments by PureTech Health, Arterial Capital Management and Mitra Biotech.
Wolfe steps down to become senior advisor but remains a vocal critic of the pharmaceutical industry and FDA, as his appearance at the Avandia advisory committee meeting demonstrated.
AstraZeneca’s biologics unit MedImmune acquired AlphaCore Pharma, the developer of an early-stage asset with a novel mechanism for removing cholesterol from the body and raising “good” HDL cholesterol.
David Simmons, head of established products and emerging markets at Pfizer, has jumped ship to lead global CRO PPD Inc. Olivier Brandicourt, currently head of primary care at the big pharma, will take Simmons’ place.
- Drug Discovery Tools
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Johnson & Johnson
- Senior Management
Julian Bertschinger, PhD, CEO
Dragan Grabulovski, PhD, CSO
Elias Papatheodorou, CBO
- Contact Info
Phone: (49) 44 732 46 60
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.